Skip to main content

Cynthia Ann Moylan

Professor of Medicine
Medicine, Gastroenterology
Duke Box 3256, 595 LaSalle GSRB 1, Durham, NC 27710
Duke South Clinic, 40 Medicine Circle, Room 0350, Durham, NC 27710

Overview


My research interests focus on the study of chronic liver disease and primary liver cancer, particularly from metabolic dysfunction associated steatotic liver disease (MASLD), formerly called nonalcoholic fatty liver disease (NAFLD).  As part of the MASLD Research Team at Duke, we are investigating the role of environmental contaminants, epigenetics, and genetics on the development of advanced fibrosis and liver cancer from MASLD and other chronic liver diseases.  We are also interested in understanding risks for progressive liver disease including developmental programming and in utero exposures and have been investigating these risks through studies of the Newborn Epigenetics Study (NEST).  The long term goal of our research is to develop non-invasive biomarkers to identify those patients at increased risk for cirrhosis and end stage liver disease in order to risk stratify patients as well as to develop better preventative and therapeutic strategies.

Current Appointments & Affiliations


Professor of Medicine · 2025 - Present Medicine, Gastroenterology, Medicine
Associate Professor in Pathology · 2018 - Present Pathology, Clinical Science Departments
Member of the Duke Cancer Institute · 2014 - Present Duke Cancer Institute, Institutes and Centers

Recent Publications


Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction-associated steatotic liver diseases: Target trial emulation using real-world data.

Journal Article Hepatology · February 1, 2026 BACKGROUND AND AIMS: Angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) prevent fibrosis progression in a preclinical model of steatotic liver disease. Our objective was to assess the impact of ACEi/ARB use on clinical ... Full text Link to item Cite

Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study).

Journal Article JHEP Rep · February 2026 Abdominal ultrasound every 6 months with or without serum alpha-fetoprotein (AFP) is recommended for hepatocellular carcinoma (HCC) screening in patients with cirrhosis. However, high-quality evidence demonstrating that this screening strategy reduces HCC- ... Full text Link to item Cite

Lessons learned from viral hepatitis testing that inform law and policy responses to steatotic liver disease.

Journal Article Nat Rev Gastroenterol Hepatol · January 30, 2026 Liver diseases account for 1 in 25 deaths worldwide. Owing to the asymptomatic nature across the dynamic spectrum of steatotic liver disease (SLD) and the absence of targeted screening programmes, individuals at risk of progression to cirrhosis or hepatoce ... Full text Link to item Cite
View All Publications

Recent Grants


Genomic Imprinting in the Development of NAFLD

ResearchPrincipal Investigator · Awarded by National Institute of Diabetes and Digestive and Kidney Diseases · 2024 - 2028

Therapeutic modulation of a proteomic HCC risk signature with statins in patients with liver cirrhosis

ResearchCo-Principal Investigator · Awarded by University of Texas - Southwestern · 2023 - 2027

The Southeastern Liver Health Cohort Study

ResearchPrincipal Investigator · Awarded by North Carolina State University · 2023 - 2027

View All Grants

Education, Training & Certifications


University of Miami · 2002 M.D.